Letter regarding “Clinical features, diagnosis, and survival analysis of dogs with glioma”

Bley, Carla Rohrer; Meier, Valeria; Beckmann, Katrin; Steffen, Frank

doi:10.1111/jvim.16492

Veterinary Internal Medicne

2022

DOI: 10.1111/jvim.16492

|View full text |Cite

Letter regarding “Clinical features, diagnosis, and survival analysis of dogs with glioma”

Carla Rohrer Bley

Valeria Meier

Katrin Beckmann

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Chemotherapy for the treatment of intracranial glioma in dogs

José-López

2023

Front. Vet. Sci.

View full text Add to dashboard Cite

Gliomas are the second most common primary brain tumor in dogs and although they are associated with a poor prognosis, limited data are available relating to the efficacy of standard therapeutic options such as surgery, radiation and chemotherapy. Additionally, canine glioma is gaining relevance as a naturally occurring animal model that recapitulates human disease with fidelity. There is an intense comparative research drive to test new therapeutic approaches in dogs and assess if results translate efficiently into human clinical trials to improve the poor outcomes associated with the current standard-of-care. However, the paucity of data and controversy around most appropriate treatment for intracranial gliomas in dogs make comparisons among modalities troublesome. To further inform therapeutic decision-making, client discussion, and future studies evaluating treatment responses, the outcomes of 127 dogs with intracranial glioma, either presumed (n = 49) or histologically confirmed (n = 78), that received chemotherapy as leading or adjuvant treatment are reviewed here. This review highlights the status of current chemotherapeutic approaches to intracranial gliomas in dogs, most notably temozolomide and lomustine; areas of novel treatment currently in development, and difficulties to consensuate and compare different study observations. Finally, suggestions are made to facilitate evidence-based research in the field of canine glioma therapeutics.

show abstract

Chemotherapy for the treatment of intracranial glioma in dogs

José-López

2023

Front. Vet. Sci.

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Letter regarding “Clinical features, diagnosis, and survival analysis of dogs with glioma”

Cited by 1 publication

References 9 publications

Chemotherapy for the treatment of intracranial glioma in dogs

Chemotherapy for the treatment of intracranial glioma in dogs

Contact Info

Product

Resources

About